1.
Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen–host interactions in Pseudomonas
aeruginosa pneumonia. American journal of respiratory and critical care medicine.
2005;171(11):1209-23.
2.
Hosseini SMJ, Naeini NS, Khaledi A, Daymad SF, Esmaeili D. Evaluate the Relationship
Between Class 1 Integrons and Drug Resistance Genes in Clinical Isolates of Pseudomonas
aeruginosa. The open microbiology journal. 2016;10:188.
3.
Mobaraki S, Aghazadeh M, Barhaghi MHS, Memar MY, Goli HR, Gholizadeh P, et al. Prevalence
of integrons 1, 2, 3 associated with antibiotic resistance in Pseudomonas aeruginosa
isolates from Northwest of Iran. BioMedicine. 2018;8(1).
4.
Rossolini G, Mantengoli E. Treatment and control of severe infections caused by multiresistant
Pseudomonas aeruginosa. Clinical Microbiology and Infection. 2005;11:17-32.
5.
Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam
for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical
effectiveness and evolution of resistance. Clinical Infectious Diseases. 2017;65(1):110-20.
6.
Ruiz-Garbajosa P, Canton R. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa.
Implications for empiric and definitive therapy. Revista Española de Quimioterapia.
2017;30.
7.
Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate
point-prevalence survey of health care–associated infections. New England Journal
of Medicine. 2014;370(13):1198-208.
8.
Palomar M, Álvarez-Lerma F, Olaechea P, Insausti J, López-Pueyo M. Estudio nacional
de vigilancia de infección nosocomial en servicios de medicina intensiva. SEMICYUC[Consultado
el 10 dic 2014] Disponible en: URL: http://hwsvhebron net/envin-helics/Help/Informe% 20ENVIN-UCI. 2008;202012.
9.
Oliver A, Mulet X, Lopez-Causape C, Juan C. The increasing threat of Pseudomonas aeruginosa
high-risk clones. Drug Resistance Updates. 2015;21:41-59.
10.
Vaez H, Salehi-Abargouei A, Ghalehnoo ZR, Khademi F. Multidrug resistant Pseudomonas
aeruginosa in Iran: A systematic review and metaanalysis. Journal of global infectious
diseases. 2018;10(4):212.
11.
Carattoli A. Importance of integrons in the diffusion of resistance. Veterinary research.
2001;32(3-4):243-59.
12.
Ruiz-Martínez L, López-Jiménez L, Fusté E, Vinuesa T, Martínez J, Viñas M. Class 1
integrons in environmental and clinical isolates of Pseudomonas aeruginosa. International
journal of antimicrobial agents. 2011;38(5):398-402.
13.
Gu B, Tong M, Zhao W, Liu G, Ning M, Pan S, et al. Prevalence and characterization
of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates
from patients in Nanjing, China. Journal of clinical microbiology. 2007;45(1):241-3.
14.
Mazel D, Dychinco B, Webb VA, Davies J. Antibiotic resistance in the ECOR collection:
integrons and identification of a novel aad gene. Antimicrobial Agents and Chemotherapy.
2000;44(6):1568-74.
15.
Gillings MR, Gaze WH, Pruden A, Smalla K, Tiedje JM, Zhu Y-G. Using the class 1 integron-integrase
gene as a proxy for anthropogenic pollution. The ISME journal. 2015;9(6):1269.
16.
Deng Y, Bao X, Ji L, Chen L, Liu J, Miao J, et al. Resistance integrons: class 1,
2 and 3 integrons. Annals of clinical microbiology and antimicrobials. 2015;14(1):45.
17.
Hall RM, Collis CM. Antibiotic resistance in gram-negative bacteria: the role of gene
cassettes and integrons. Drug resistance UPDATES. 1998;1(2):109-19.
18.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation
and elaboration. Annals of internal medicine. 2007;147(8):W-163-W-94.
19.
Phu VD, Wertheim HF, Larsson M, Nadjm B, Dinh Q-D, Nilsson LE, et al. Burden of hospital
acquired infections and antimicrobial use in Vietnamese adult intensive care units.
PloS one. 2016;11(1):e0147544.
20.
Faghri J, Nouri S, Jalalifar S, Zalipoor M, Halaji M. Investigation of antimicrobial
susceptibility, class I and II integrons among Pseudomonas aeruginosa isolates from
hospitalized patients in Isfahan, Iran. BMC research notes. 2018;11(1):806.
21.
Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, et al. Multiple
antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients
with cystic fibrosis. Journal of Cystic Fibrosis. 2012;11(4):293-9.
22.
Cholley P, Thouverez M, Hocquet D, Van Der Mee-Marquet N, Talon D, Bertrand X. Most
multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France
belong to a few clonal types. Journal of clinical microbiology. 2011;49(7):2578-83.
23.
Taccone FS, Cotton F, Roisin S, Vincent J-L, Jacobs F. Optimal meropenem concentrations
to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrobial agents
and chemotherapy. 2012;56(4):2129-31.
24.
Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, et al. PCR typing of
genetic determinants for metallo-β-lactamases and integrases carried by gram-negative
bacteria isolated in Japan, with focus on the class 3 integron. Journal of Clinical
Microbiology. 2003;41(12):5407-13.
25.
Shahandashti EF, Molana Z, Asgharpour F, Mojtahedi A, Rajabnia R. Molecular detection
of Integron genes and pattern of antibiotic resistance in Pseudomonas aeruginosa strains
isolated from intensive care unit, Shahid Beheshti Hospital, North of Iran. International
journal of molecular and cellular medicine. 2012;1(4):209.
26.
Chen J, Su Z, Liu Y, Wang S, Dai X, Li Y, et al. Identification and characterization
of class 1 integrons among Pseudomonas aeruginosa isolates from patients in Zhenjiang,
China. International Journal of Infectious Diseases. 2009;13(6):717-21.
27.
Fonseca ÉL, Vieira VV, Cipriano R, Vicente AC. Class 1 integrons in Pseudomonas aeruginosa
isolates from clinical settings in Amazon region, Brazil. FEMS Immunology & Medical
Microbiology. 2005;44(3):303-9.
28.
Fernández L, Álvarez-Ortega C, Wiegand I, Olivares J, Kocíncová D, Lam JS, et al.
Characterization of the polymyxin B resistome of Pseudomonas aeruginosa. Antimicrobial
agents and chemotherapy. 2013;57(1):110-9.
29.
Gelband H, Molly Miller P, Pant S, Gandra S, Levinson J, Barter D, et al. The state
of the world's antibiotics 2015. Wound Healing Southern Africa. 2015;8(2):30-4.
30.
Gales A, Jones R, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas
aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and
molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999.
Clinical Infectious Diseases. 2001;32(Supplement_2):S146-S55.
31.
Brown PD, Izundu A. Antibiotic resistance in clinical isolates of Pseudomonas aeruginosa
in Jamaica. Revista Panamericana de Salud Pública. 2004;16:125-30.
32.
Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz M. Pseudomonas aeruginosa: a
survey of resistance in 136 hospitals in Spain. Antimicrobial Agents and chemotherapy.
1999;43(4):981-2.
33.
Poonsuk K, Tribuddharat C, Chuanchuen R. Class 1 integrons in Pseudomonas aeruginosa
and Acinetobacter baumannii isolated from clinical isolates. Southeast Asian Journal
of Tropical Medicine and Public Health. 2012;43(2):376.
34.
Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology
of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus
aureus isolates. PloS one. 2015;10(8):e0136082.
35.
Jabalameli F, Taki E, Emaneini M, Beigverdi R. Prevalence of metallo-β-lactamase-encoding
genes among carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn
patients in Iran. Revista da Sociedade Brasileira de Medicina Tropical. 2018;51(3):270-6.
36.
Ider B-E, Adams J, Morton A, Whitby M, Clements A. Perceptions of healthcare professionals
regarding the main challenges and barriers to effective hospital infection control
in Mongolia: a qualitative study. BMC infectious diseases. 2012;12(1):170.
37.
Yousefi S, Nahaei M, Farajnia S, Ghojazadeh M, Akhi M, Sharifi Y, et al. Class 1 integron
and imipenem resistance in clinical isolates of Pseudomonas aeruginosa: prevalence
and antibiotic susceptibility. Iranian journal of microbiology. 2010;2(3):115.
38.
Nikokar I, Tishayar A, Flakiyan Z, Alijani K, Rehana-Banisaeed S, Hossinpour M, et
al. Antibiotic resistance and frequency of class 1 integrons among Pseudomonas aeruginosa,
isolated from burn patients in Guilan, Iran. Iranian journal of microbiology. 2013;5(1):36.
39.
GOUDARZI SM, Eftekhar F. Multidrug resistance and integron carriage in clinical isolates
ofPseudomonas aeruginosa in Tehran, Iran. Turkish journal of medical sciences. 2015;45(4):789-93.
40.
Goudarzi M, Fazeli M, Azad M, Seyedjavadi S, Mousavi R, Rashidan M, et al. Carriage
of Class 1 and Class 2 Integron in Multidrug Resistant Pseudomonas aeruginosa Isolated
from Burn Patients in Tehran Hospitals, Iran. West Indian Medical Journal. 2016;65(1).
41.
Aryanezhad M, Shakibaie MR, Karmostaji A, Shakibaie S. Prevalence of Class 1, 2, and
3 Integrons and Biofilm Formation in Pseudomonas aeruginosa and Acinetobacter baumannii
among ICU and non-ICU Patients. Infect Epidemiol Med. 2016.
42.
Mirahsani M, Khorshidi A, Moniri R, Gilasi HR. Prevalence of Class 1 Integron, Resistance
Gene Cassettes and Antimicrobial Susceptibility Profiles among Isolates of Pseudomonas
aeruginosa in Iran. Open Journal of Medical Microbiology. 2016;6(02):87.
43.
Goli HR, Nahaei MR, Rezaee MA, Hasani A, Kafil HS, Aghazadeh M, et al. Prevalence
and molecular characterization of Class 1 integrons among clinical isolates of Pseudomonas
aeruginosa in Northwest of Iran. Molecular Genetics, Microbiology and Virology. 2017;32(2):109-15.
44.
Khosravi AD, Motahar M, Montazeri EA. The frequency of class1 and 2 integrons in Pseudomonas
aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran. PloS
one. 2017;12(8):e0183061.
45.
Mohammadzadeh A, Mardaneh J, Ahmadi R, Adabi J. Evaluation of the virulence features
and antibiotic resistance patterns of pathogenic Pseudomonas aeruginosa strains isolated
from hospitalized patients in Gonabad, Iran. Archives of Pediatric Infectious Diseases.
2017;5(3).
46.
Goli HR, Nahaei MR, Rezaee MA, Hasani A, Kafil HS, Aghazadeh M, et al. Role of MexAB-OprM
and MexXY-OprM efflux pumps and class 1 integrons in resistance to antibiotics in
burn and Intensive Care Unit isolates of Pseudomonas aeruginosa. Journal of infection
and public health. 2018;11(3):364-72.
47.
Pournajaf A, Razavi S, Irajian G, Ardebili A, Erfani Y, Solgi S, et al. Integron types,
antimicrobial resistance genes, virulence gene profile, alginate production and biofilm
formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates. Infez Med. 2018;26(3):226-36.
48.
Zarei-Yazdeli M, Eslami G, Zandi H, Kiani M, Barzegar K, Alipanah H, et al. Prevalence
of class 1, 2 and 3 integrons among multidrug-resistant Pseudomonas aeruginosa in
Yazd, Iran. Iranian journal of microbiology. 2018;10(5):300.
49.
Salimizadeh Z, Karouei H, Masoud S, Hosseini F. Dissemination of Class 1 Integron
among Different Multidrug Resistant Pseudomonas aeruginosa Strains. Medical Laboratory
Journal. 2018;12(4):36-42.